Skip to main content
SpringerLink
Log in

Fragile X Syndrome

  • Chapter
Health Care for People with Intellectual and Developmental Disabilities across the Lifespan

Abstract

Fragile X syndrome and the associated disorders account for a wide range of clinical symptoms that require proper behavioral and pharmacological intervention. Early diagnosis is crucial to maximizing successful interventions and once one child is diagnosed, families should be referred for genetic counseling to establish the possible implications for additional family members and future family planning. This section reviews the phenotypes and neurobiology of the full mutation and premutation as well as possible potential interventions for both sets of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 389.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 499.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Martin JP, Bell J. A pedigree of mental defect showing sex-linkage. J Neurol Psychiatry. 1943;6(3–4):154.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Lubs HA. A marker x chromosome. Am J Hum Genet. 1969;21(3):231.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Tassone F, Hagerman RJ, Taylor AK, Gane LW, Godfrey TE, Hagerman PJ. Elevated levels of fmr1 mrna in carrier males: a new mechanism of involvement in the fragile-x syndrome. Am J Hum Genet. 2000;66(1):6–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Hagerman R, Hagerman P. Advances in clinical and molecular understanding of the fmr1 premutation and fragile x-associated tremor/ataxia syndrome. Lancet Neurol. 2013;12(8):786–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Goodlin-Jones BL, Tassone F, Gane LW, Hagerman RJ. Autistic spectrum disorder and the fragile x premutation. J Dev Behav Pediatr. 2004;25(6):392–8.

    Article  PubMed  Google Scholar 

  6. Hunter J, Rivero-Arias O, Angelov A, Kim E, Fotheringham I, Leal J. Epidemiology of fragile x syndrome: a systematic review and meta-analysis. Am J Med Genet A. 2014;164A:1648.

    Article  PubMed  Google Scholar 

  7. Tassone F. Newborn screening in fragile x syndrome. JAMA. 2014;71(3):355–9.

    Google Scholar 

  8. Hagerman RJ, Hagerman PJ. Fragile x syndrome: diagnosis, treatment, and research. Baltimore: John Hopkins University Press; 2002.

    Book  Google Scholar 

  9. McConkie-Rosell A, Lachiewicz A, Spiridigliozzi G, Tarleton J, Schoenwald S, Phelan M, et al. Evidence that methylation of the fmr-i locus is responsible for variable phenotypic expression of the fragile x syndrome. Am J Hum Genet. 1993;53(4):800–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Schaefer GB, Mendelsohn NJ. Genetics evaluation for the etiologic diagnosis of autism spectrum disorders. Genet Med. 2008;10(1):4–12.

    Article  PubMed  Google Scholar 

  11. Hatton DD, Sideris J, Skinner M, Mankowski J, Bailey DB, Roberts J, et al. Autistic behavior in children with fragile x syndrome: prevalence, stability, and the impact of fmrp. Am J Med Genet Part A. 2006;140A(17):1804–13.

    Article  PubMed  Google Scholar 

  12. Harris SW, Hessl D, Goodlin-Jones B, Ferranti J, Bacalman S, Barbato I, et al. Autism profiles of males with fragile x syndrome. Am J Ment Retard. 2008;113(6):427–38.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Wilding J, Cornish K, Munir F. Further delineation of the executive deficit in males with fragile-x syndrome. Neuropsychologia. 2002;40(8):1343–9.

    Article  PubMed  Google Scholar 

  14. Munir F, Cornish KM, Wilding J. Nature of the working memory deficit in fragile-x syndrome. Brain Cogn. 2000;44(3):387–401.

    Article  CAS  PubMed  Google Scholar 

  15. Cornish KM, Munir F, Cross G. Spatial cognition in males with fragile-x syndrome: evidence for a neuropsychological phenotype. Cortex. 1999;35(2):263–71.

    Article  CAS  PubMed  Google Scholar 

  16. Chonchaiya W, Au J, Schneider A, Hessl D, Harris SW, Laird M, et al. Increased prevalence of seizures in boys who were probands with the fmr1 premutation and co-morbid autism spectrum disorder. Hum Genet. 2012;131(4):581–9.

    Article  PubMed  Google Scholar 

  17. Wirojanan J, Jacquemont S, Diaz R, Bacalman S, Anders TF, Hagerman RJ, et al. The efficacy of melatonin for sleep problems in children with autism, fragile x syndrome, or autism and fragile x syndrome. J Clin Sleep Med. 2009;5(2):145–50.

    PubMed  PubMed Central  Google Scholar 

  18. Roberts JE, Bailey DB, Mankowski J, Ford A, Sideris J, Weisenfeld LA, et al. Mood and anxiety disorders in females with the fmr1 premutation. Am J Med Genet Part B. 2009;150(1):130–9.

    Article  Google Scholar 

  19. Bourgeois JA, Seritan AL, Casillas EM, Hessl D, Schneider A, Yang Y, et al. Lifetime prevalence of mood and anxiety disorders in fragile x premutation carriers. J Clin Psychiatry. 2011;72(2):175–82.

    Article  PubMed  Google Scholar 

  20. Hamlin A, Liu Y, Nguyen DV, Tassone F, Zhang L, Hagerman RJ. Sleep apnea in fragile x premutation carriers with and without fxtas. Am J Med Genet Part B. 2011;156b(8):923–8.

    Article  PubMed  Google Scholar 

  21. Au J, Akins RS, Berkowitz-Sutherland L, Tang HT, Chen Y, Boyd A, et al. Prevalence and risk of migraine headaches in adult fragile x premutation carriers. Clin Genet. 2013;84(6):546–51.

    Article  CAS  PubMed  Google Scholar 

  22. Sullivan SD, Welt C, Sherman S. Fmr1 and the continuum of primary ovarian insufficiency. Semin Reprod Med. 2011;29(04):299–307.

    Article  PubMed  Google Scholar 

  23. Utari A, Chonchaiya W, Rivera SM, Schneider A, Hagerman RJ, Faradz SM, et al. Side effects of minocycline treatment in patients with fragile x syndrome and exploration of outcome measures. Am J Intellect Dev Disabil. 2010;115(5):433–43.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Greco CM, Navarro CS, Hunsaker MR, Maezawa I, Shuler JF, Tassone F, et al. Neuropathologic features in the hippocampus and cerebellum of three older men with fragile x syndrome. Mol Autism. 2011;2(1):2.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Fatemi S, Folsom T, Rooney R, Thuras P. Mrna and protein expression for novel gabaa receptors θ and ρ2 are altered in schizophrenia and mood disorders; relevance to fmrp-mglur5 signaling pathway. Translat Psychiatry. 2013;3(6), e271.

    Article  CAS  Google Scholar 

  26. Brown V, Jin P, Ceman S, Darnell JC, O'Donnell WT, Tenenbaum SA, et al. Microarray identification of fmrp-associated brain mrnas and altered mrna translational profiles in fragile x syndrome. Cell. 2001;107(4):477–87.

    Article  CAS  PubMed  Google Scholar 

  27. Massey PV, Bashir ZI. Long-term depression: multiple forms and implications for brain function. Trends Neurosci. 2007;30(4):176–84.

    Article  CAS  PubMed  Google Scholar 

  28. Bear MF, Huber KM, Warren ST. The mglur theory of fragile x mental retardation. Trends Neurosci. 2004;27(7):370–7.

    Article  CAS  PubMed  Google Scholar 

  29. Dölen G, Carpenter RL, Ocain TD, Bear MF. Mechanism-based approaches to treating fragile x. Pharmacol Ther. 2010;127(1):78–93.

    Article  PubMed  Google Scholar 

  30. Qin M, Kang J, Burlin TV, Jiang C, Smith CB. Postadolescent changes in regional cerebral protein synthesis: an in vivo study in the fmr1 null mouse. J Neurosci. 2005;25(20):5087–95.

    Article  CAS  PubMed  Google Scholar 

  31. Gross C, Nakamoto M, Yao X, Chan C-B, Yim SY, Ye K, et al. Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile x syndrome. J Neurosci. 2010;30(32):10624–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Belmonte MK, Bourgeron T. Fragile x syndrome and autism at the intersection of genetic and neural networks. Nat Neurosci. 2006;9(10):1221–5.

    Article  CAS  PubMed  Google Scholar 

  33. Rubenstein J, Merzenich M. Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav. 2003;2(5):255–67.

    Article  CAS  PubMed  Google Scholar 

  34. Moy SS, Nadler JJ. Advances in behavioral genetics: mouse models of autism. Mol Psychiatry. 2008;13(1):4–26.

    Article  CAS  PubMed  Google Scholar 

  35. Berry-Kravis E, Grossman AW, Crnic LS, Greenough WT. Understanding fragile x syndrome. Curr Paediatrics. 2002;12(4):316–24.

    Article  Google Scholar 

  36. Hagerman RJ, Berry-Kravis E, Kaufmann WE, Ono MY, Tartaglia N, Lachiewicz A, et al. Advances in the treatment of fragile x syndrome. Pediatrics. 2009;123(1):378–90.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Gatto CL, Broadie K. Genetic controls balancing excitatory and inhibitory synaptogenesis in neurodevelopmental disorder models. Front Synaptic Neurosci. 2010;2:4.

    PubMed  PubMed Central  Google Scholar 

  38. Cordeiro L, Ballinger E, Hagerman R, Hessl D. Clinical assessment of dsm-iv anxiety disorders in fragile x syndrome: prevalence and characterization. J Neurodev Disord. 2011;3(1):57–67.

    Article  PubMed  Google Scholar 

  39. Olmos-Serrano JL, Paluszkiewicz SM, Martin BS, Kaufmann WE, Corbin JG, Huntsman MM. Defective gabaergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile x syndrome. J Neurosci. 2010;30(29):9929–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Acharya K, Schindler A. Developmental and behavioral pediatricians' attitudes toward screening for fragile x. Am J Intellect Dev Disabil. 2013;118(4):284–93.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Restivo L, Ferrari F, Passino E, Sgobio C, Bock J, Oostra BA, et al. Enriched environment promotes behavioral and morphological recovery in a mouse model for the fragile x syndrome. Proc Natl Acad Sci U S A. 2005;102(32):11557–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Moskowitz LJ, Carr EG, Durand VM. Behavioral intervention for problem behavior in children with fragile x syndrome. Am J Intellect Dev Disabil. 2011;116(6):457–78.

    Article  PubMed  Google Scholar 

  43. Winarni TI, Schneider A, Borodyanskara M, Hagerman RJ. Early intervention combined with targeted treatment promotes cognitive and behavioral improvements in young children with fragile x syndrome. Case Rep Genet. 2012;2012:280813.

    PubMed  PubMed Central  Google Scholar 

  44. Erickson CA, Stigler KA, Wink LK, Mullett JE, Kohn A, Posey DJ, et al. A prospective open-label study of aripiprazole in fragile x syndrome. Psychopharmacology (Berl). 2011;216(1):85–90.

    Article  CAS  Google Scholar 

  45. Berry-Kravis E, Sumis A, Hervey C, Mathur S. Clinic-based retrospective analysis of psychopharmacology for behavior in fragile x syndrome. Int J Pediatr. 2012;2012:843016.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Tassone F, Hagerman R. The fragile x-associated tremor ataxia syndrome. Results Probl Cell Differ. 2012;54:337–57.

    Article  CAS  PubMed  Google Scholar 

  47. Bailey Jr DB, Raspa M, Bishop E, Olmsted M, Mallya UG, Berry-Kravis E. Medication utilization for targeted symptoms in children and adults with fragile x syndrome: US survey. J Dev Behav Pediatrics. 2012;33(1):62–9.

    Article  Google Scholar 

  48. Siller SS, Broadie K. Neural circuit architecture defects in a drosophila model of fragile x syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinase. Dis Model Mech. 2011;4(5):673–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Bilousova TV, Dansie L, Ngo M, Aye J, Charles JR, Ethell DW, Ethell IM. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile x mouse model. J Med Genet. 2009;46(2):94–102.

    Article  CAS  PubMed  Google Scholar 

  50. Rotschafer SE, Trujillo MS, Dansie LE, Ethell IM, Razak KA. Minocycline treatment reverses ultrasonic vocalization production deficit in a mouse model of fragile x syndrome. Brain Res. 2012;1439:7–14.

    Article  CAS  PubMed  Google Scholar 

  51. Paribello C, Tao L, Folino A, Berry-Kravis E, Tranfaglia M, Ethell I, et al. Open-label add-on treatment trial of minocycline in fragile x syndrome. BMC Neurol. 2010;10(1):91.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Leigh MJ, Nguyen DV, Mu Y, Winarni TI, Schneider A, Chechi T, et al. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome. J Dev Behav Pediatr. 2013;34(3):147–55.

    Article  PubMed  PubMed Central  Google Scholar 

  53. McBride SM, Holloway SL, Jongens TA. Using drosophila as a tool to identify pharmacological therapies for fragile x syndrome. Drug Discov Today Technol. 2013;10(1):e129–36.

    Article  PubMed  Google Scholar 

  54. Yuskaitis CJ, Mines MA, King MK, Sweatt JD, Miller CA, Jope RS. Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile x syndrome. Biochem Pharmacol. 2010;79(4):632–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Berry-Kravis E, Knox A, Hervey C. Targeted treatments for fragile x syndrome. J Neurodev Disord. 2011;3(3):193–210.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Berry-Kravis E, Sumis A, Hervey C, Nelson M, Porges SW, Weng N, et al. Open-label treatment trial of lithium to target the underlying defect in fragile x syndrome. J Dev Behav Pediatr. 2008;29(4):293–302.

    Article  PubMed  Google Scholar 

  57. Berry-Kravis E, Hessl D, Coffey S, Hervey C, Schneider A, Yuhas J, et al. A pilot open label, single dose trial of fenobam in adults with fragile x syndrome. J Med Genet. 2009;46(4):266–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Jacquemont S, Curie A, des Portes V, Torrioli MG, Berry-Kravis E, Hagerman RJ, et al. Epigenetic modification of the fmr1 gene in fragile x syndrome is associated with differential response to the mglur5 antagonist afq056. Sci Transl Med 2011;3(64):64ra1.

    Google Scholar 

  59. Berry-Kravis EM, Hessl D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen K, et al. Effects of stx209 (arbaclofen) on neurobehavioral function in children and adults with fragile x syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med. 2012;4(152):152ra127.

    Article  PubMed  Google Scholar 

  60. Sansone SM, Widaman KF, Hall SS, Reiss AL, Lightbody A, Kaufmann WE, et al. Psychometric study of the aberrant behavior checklist in fragile x syndrome and implications for targeted treatment. J Autism Dev Disord. 2012;42(7):1377–92.

    Article  PubMed  PubMed Central  Google Scholar 

  61. D’Hulst C, De Geest N, Reeve SP, Van Dam D, De Deyn PP, Hassan BA, et al. Decreased expression of the gaba-a receptor in fragile x syndrome. Brain Res. 2006;1121(1):238–45.

    Article  PubMed  Google Scholar 

  62. D’Hulst C, Heulens I, Brouwer JR, Willemsen R, De Geest N, Reeve SP, et al. Expression of the gabaergic system in animal models for fragile x syndrome and fragile x associated tremor/ataxia syndrome (fxtas). Brain Res. 2009;1253:176–83.

    Article  PubMed  Google Scholar 

  63. Erickson C, Wink L, Ray B, Early M, Stiegelmeyer E, Mathieu-Frasier L, et al. Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile x syndrome. Psychopharmacol (Berl). 2013;228(1):75–84.

    Article  CAS  Google Scholar 

  64. al Qatari M, Bouchenafa O, Littleton J. Mechanism of action of acamprosate. Part ii. Ethanol dependence modifies effects of acamprosate on nmda receptor binding in membranes from rat cerebral cortex. Alcohol Clin Exp Res. 1998;22(4):810–4.

    Article  CAS  PubMed  Google Scholar 

  65. McDuffie A, Kover ST, Hagerman R, Abbeduto L. Investigating word learning in fragile x syndrome: a fast-mapping study. J Autism Dev Disord. 2013;43(7):1676–91.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Finestack LH, Richmond EK, Abbeduto L. Language development in individuals with fragile x syndrome. Topics Lang Disord. 2009;29(2):133–48.

    Article  Google Scholar 

  67. Brady N, Skinner D, Roberts J, Hennon E. Communication in young children with fragile x syndrome: a qualitative study of mothers' perspectives. Am J Speech Lang Pathol. 2006;15(4):353–64.

    Article  PubMed  Google Scholar 

  68. Oakes A, Kover ST, Abbeduto L. Language comprehension profiles of young adolescents with fragile x syndrome. Am J Speech Lang Pathol. 2013;22(4):615–26.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Martin GE, Losh M, Estigarribia B, Sideris J, Roberts J. Longitudinal profiles of expressive vocabulary, syntax and pragmatic language in boys with fragile x syndrome or down syndrome. Int J Lang Commun Disord. 2013;48(4):432–43.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Roberts JE, Hennon EA, Price JR, Dear E, Anderson K, Vandergrift NA. Expressive language during conversational speech in boys with fragile x syndrome. Am J Ment Retard. 2007;112(1):1–17.

    Article  PubMed  Google Scholar 

  71. Martin GE, Ausderau KK, Raspa M, Bishop E, Mallya U, Bailey Jr DB. Therapy service use among individuals with fragile x syndrome: findings from a US parent survey. J Intellect Disabil Res. 2013;57(9):837–49.

    Article  CAS  PubMed  Google Scholar 

  72. Fey ME, Warren SF, Brady N, Finestack LH, Bredin-Oja SL, Fairchild M, et al. Early effects of responsivity education/prelinguistic milieu teaching for children with developmental delays and their parents. J Speech Lang Hear Res. 2006;49(3):526–47.

    Article  PubMed  Google Scholar 

  73. Sussman F, Lewis RB. More than words: a guide to helping parents promote communication and social skills in children with autism spectrum disorder. Toronto: Hanen Centre; 1999.

    Google Scholar 

  74. Charlop-Christy M, Jones C. The picture exchange communication system. In: McCauley R, Fey M, editors. Treatment of language disorders in children. Baltimore: Paul H Brookes; 2006. p. 105–22.

    Google Scholar 

  75. Mirrett PL, Roberts JE, Price J. Early intervention practices and communication intervention strategies for young males with fragile x syndrome. Lang Speech Hear Serv Schools. 2003;34(4):320.

    Article  Google Scholar 

  76. Scharfenaker S, O’Connor R, Stackhouse T, Braden M, Hickman L, Gray K. An integrated approach to intervention. In: Hagerman RJ, Hagerman PJ, editors. Fragile x syndrome: diagnosis, treatment, and research. Baltimore: John Hopkins University Press; 2002. p. 349–411.

    Google Scholar 

  77. Baranek GT, Chin YH, Hess LM, Yankee JG, Hatton DD, Hooper SR. Sensory processing correlates of occupational performance in children with fragile x syndrome: preliminary findings. Am J Occup Ther. 2002;56(5):538–46.

    Article  PubMed  Google Scholar 

  78. Zingerevich C, Greiss-Hess L, Lemons-Chitwood K, Harris SW, Hessl D, Cook K, et al. Motor abilities of children diagnosed with fragile x syndrome with and without autism. J Intellect Disabil Res. 2009;53(1):11–8.

    Article  CAS  PubMed  Google Scholar 

  79. Dawson G, Jones EJ, Merkle K, Venema K, Lowy R, Faja S, et al. Early behavioral intervention is associated with normalized brain activity in young children with autism. J Am Acad Child Adolesc Psychiatry. 2012;51(11):1150–9.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Rogers SJ, Estes A, Lord C, Vismara L, Winter J, Fitzpatrick A, et al. Effects of a brief early start Denver model (esdm)-based parent intervention on toddlers at risk for autism spectrum disorders: a randomized controlled trial. J Am Acad Child Adolesc Psychiatry. 2012;51(10):1052–65.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Chen W. Multitouch tabletop technology for people with autism spectrum disorder: a review of the literature. Procedia Comput Sci. 2012;14:198–207.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. MIND Institute, UC Davis Health System, 2825 50th Street, Sacramento, CA, 95817, USA

    Emma Hare

  2. UC Davis Health System, 2825 50th Street, Sacramento, CA, 95817, USA

    Reymundo Lozano

  3. MIND Institute, Fragile X Research, UC Davis Health System, 2825 50th Street, Sacramento, CA, 95817, USA

    Lindsey Partington & Randi J. Hagerman M.D., FAAP

Authors
  1. Emma Hare
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Reymundo Lozano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lindsey Partington
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Randi J. Hagerman M.D., FAAP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Randi J. Hagerman M.D., FAAP .

Editor information

Editors and Affiliations

  1. Innovative Solutions for Disadvantage and Disability and Department of Pediatrics, Morehouse School of Medicine, Atlanta, GA, USA

    I. Leslie Rubin

  2. National Institute of Child Health and Human Development and Medical Services, Division for Developmental and Developmental Disabilities, Ministry of Social Affairs and Social Services, Jerusalem, Israel

    Joav Merrick

  3. Department of Pediatric and Adolescent Medicine, Western Michigan University Homer Stryker MD School of Medicine, Western Michigan University, Kalamazoo, MI, USA

    Donald E. Greydanus  & Dilip R. Patel  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Hare, E., Lozano, R., Partington, L., Hagerman, R.J. (2016). Fragile X Syndrome. In: Rubin, I.L., Merrick, J., Greydanus, D.E., Patel, D.R. (eds) Health Care for People with Intellectual and Developmental Disabilities across the Lifespan. Springer, Cham. https://doi.org/10.1007/978-3-319-18096-0_64

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-18096-0_64

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-18095-3

  • Online ISBN: 978-3-319-18096-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation